Treating Depression during Pregnancy: Are We Asking the Right Questions?

Area of Science:

• Perinatal Psychiatry
• Pharmacology
• Obstetrics

Background:

• Major depressive disorder (MDD) is a significant complication during pregnancy.
• Physicians must develop individualized treatment plans for pregnant women diagnosed with MDD.

Purpose of the Study:

• To outline strategies for managing MDD in pregnant women.
• To emphasize the importance of risk-benefit analysis when considering antidepressant use during pregnancy.
• To provide guidance on optimizing antidepressant dosing throughout pregnancy and postpartum.

Main Methods:

• Evaluating the benefits of antidepressant medication for maternal health against potential risks to the embryo-fetus.
• Individualizing treatment decisions based on disease characteristics, treatment response, fetal risks, and patient values.
• Monitoring and adjusting selective serotonin reuptake inhibitor (SSRI) doses during pregnancy and postpartum.

Main Results:

• No treatment approach for pregnant women with MDD is entirely risk-free; both the disorder and medications pose risks.
• Antidepressant medication is justified when the risks associated with untreated MDD outweigh the potential risks of the medication.
• The primary goal of treatment is symptom remission to minimize risks to both mother and fetus.

Conclusions:

• Optimizing SSRI dosing during pregnancy involves finding the best dose for maternal response with tolerable side effects.
• Pharmacokinetic changes during pregnancy necessitate continuous symptom monitoring and potential dose adjustments.
• Postpartum, dose adjustments are required to manage the transition to a nonpregnant, breastfeeding state.